Showing 4211-4220 of 6036 results for "".
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef
- GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with Lumevoq Gene Therapy at NANOS 2024https://modernod.com/news/gensight-biologics-announces-initial-results-from-new-meta-analyses-on-visual-outcomes-with-lumevoq-gene-therapy-at-nanos-2024/2482159/GenSight Biologics announced initial results of new meta-analyses in Leber Hereditary Optic Neuropathy (LHON), which showed those treated with Lumevoq (GS010; lenadogene nolparvovec) gene therapy experienced a rate of visual recovery greater than that of idebenone-treated patients and untreated (
- Apellis Appoints Philip Ferrone, MD, as Chief Medical Retina Advisorhttps://modernod.com/news/apellis-appoints-philip-ferrone-md-as-chief-medical-retina-advisor/2482154/Apellis Pharmaceuticals announced that retina specialist Philip Ferrone, MD, will join the company as Chief Medical Retina Advisor, effective March 18. “Phil is globally renowned for his leadership in retina, including as a past president of the American Society of Reti
- Telios Pharma Announces Phase 2 Results for TL-925, a Novel Treatment for Dry Eye Diseasehttps://modernod.com/news/telios-pharma-announces-successful-phase-2-results-for-tl-925-a-novel-treatment-for-dry-eye-disease/2482150/Telios Pharma announced topline results from its phase 2 study assessing TL-925, a first-in-class topical Bruton’s tyrosine kinase (BTK) inhibitor for individuals with moderate to severe dry eye disease (DED). This proof-of-concept, multicenter, randomized, double-masked study evaluated the
- AcrySof IQ Vivity and Clareon Vivity EDOF IOLs Reach 1 Million Implants Milestonehttps://modernod.com/news/acrysof-iq-vivity-and-clareon-vivity-edof-iols-reach-1-million-implants-milestone/2482147/Alcon announced that the AcrySof IQ Vivity and Clareon Vivity extended depth of focus (EDOF) IOLs have surpassed more than 1 million implants worldwide. Vivity is the most implanted EDOF IOL globally, according to Alcon.[1] “We are proud to celebrate
- Nicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual Meetinghttps://modernod.com/news/nicox-announces-presentation-of-data-on-ncx-470-at-the-2024-american-glaucoma-society-annual-meeting/2482143/Nicox SA provided details of poster presentations highlighting data on NCX 470 at the 2024 American Glaucoma Society (AGS) annual meeting, one of the key scientific events in vision research, which was held February 29-March 3, 2024, in Huntington Beach, California. Poster tit
- Study: Blindness from Some Inherited Eye Diseases May be Caused by Gut Bacteriahttps://modernod.com/news/study-blindness-from-some-inherited-eye-diseases-may-be-caused-by-gut-bacteria/2482140/Sight loss in certain inherited eye diseases may be caused by gut bacteria, and is potentially treatable by antimicrobials, according to a new study in mice co-led by a University College London (UCL) and Moorf
- Palitin Misses Co-Primary Endpoints in Phase 3 Dry Eye Disease Trialhttps://modernod.com/news/palitin-misses-co-primary-endpoints-in-phase-3-trial-dry-eye-disease-candidate/2482136/Palatin Technologies did not achieve statistical significance in the co-primary endpoints of its pivotal phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED). MELODY-1 had two co-primary efficacy endpoints
- Swiss Advanced Vision Launches New Features for its Toric Calculatorhttps://modernod.com/news/swiss-advanced-vision-launches-new-features-for-its-toric-calculator/2482130/Swiss Advanced Vision (SAV-IOL) announced the launch of new features for its toric calculator designed to improve the calculation experience. For the first-time, ophthalmologists will be able to use a web-based configurator to help define the best incision location to minimize resi
- Alcon to Unveil Updated MARLO App at SECO 2024https://modernod.com/news/alcon-to-unveil-new-marlo-app-at-seco-2024/2482127/Alcon announced it will showcase the new MARLO App at the SECO International meeting in Atlanta. The app includes new features for patients and is now available to download in the Apple App Store. Launched in 2020, MARLO was developed as an online platform to h